Literature DB >> 1371850

Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease.

K Blennow1, A Wallin, C G Gottfries, A Lekman, I Karlsson, I Skoog, L Svennerholm.   

Abstract

The monoamine metabolites homovanillic acid (HVA), 5-hydroxy-indoleacetic acid (5-HIAA) and 4-hydroxy-3-methoxy-phenylglycol (HMPG) were determined in lumbar cerebrospinal fluid (CSF) of 123 patients with Alzheimer's disease (AD) and 57 healthy controls. Despite CSF sampling under strictly standardized conditions, a wide variability in values among both patients and controls was found, as well as fluctuations in repeated samples from individual patients. This suggests that several unknown factors influence the lumbar CSF levels of monoamine metabolites. The AD group showed significantly lower mean levels of HVA (p less than 0.0001) and 5-HIAA (p less than 0.0001) than the control group. A relation between severity of disease and HVA was also found. The widespread neurotransmitter disturbance in AD, together with the nonspecificity of reduced lumbar HVA and 5-HIAA levels, suggests that the changes are nonspecific, secondary to the cerebral degeneration in AD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371850     DOI: 10.1016/0197-4580(92)90017-r

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  9 in total

1.  Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer's disease.

Authors:  Kazutomi Kanemaru; Hiroshi Yamanouchi
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

2.  Biomarkers of neurodegeneration - not only Alzheimer's disease and not only cerebrospinal fluid: a guest-editor's introduction.

Authors:  Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-07       Impact factor: 3.575

Review 3.  Monoamine neurons in aging and Alzheimer's disease.

Authors:  A M Palmer; S T DeKosky
Journal:  J Neural Transm Gen Sect       Date:  1993

4.  [Monoaminergic transmitters in the cerebrospinal fluid of patients with acute, chronic, and intermittent pain. Interface between pain and depression?].

Authors:  M Strittmatter; D Ostertag; K H Hoffmann; C Paulus; C Fischer; S Meyer
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

Review 5.  Monoaminergic neuropathology in Alzheimer's disease.

Authors:  Goran Šimić; Mirjana Babić Leko; Selina Wray; Charles R Harrington; Ivana Delalle; Nataša Jovanov-Milošević; Danira Bažadona; Luc Buée; Rohan de Silva; Giuseppe Di Giovanni; Claude M Wischik; Patrick R Hof
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

6.  Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.

Authors:  Tiffany W Chow; Bruce G Pollock; Norton W Milgram
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

7.  Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease.

Authors:  Kristi Henjum; Leiv Otto Watne; Kristin Godang; Nathalie Bodd Halaas; Rannveig Saksholm Eldholm; Kaj Blennow; Henrik Zetterberg; Ingvild Saltvedt; Jens Bollerslev; Anne Brita Knapskog
Journal:  Transl Psychiatry       Date:  2022-04-09       Impact factor: 6.222

8.  Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.

Authors:  Mobina Fathi; Kimia Vakili; Shirin Yaghoobpoor; Arian Tavasol; Kimia Jazi; Ramtin Hajibeygi; Sina Shool; Fatemeh Sodeifian; Andis Klegeris; Alyssa McElhinney; Mostafa Rezaei Tavirani; Fatemeh Sayehmiri
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

Review 9.  Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies.

Authors:  Anders Wallin; Arto Nordlund; Michael Jonsson; Kaj Blennow; Henrik Zetterberg; Annika Öhrfelt; Jacob Stålhammar; Marie Eckerström; Mårten Carlsson; Erik Olsson; Mattias Göthlin; Johan Svensson; Sindre Rolstad; Carl Eckerström; Maria Bjerke
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.